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CASE PRESENTATION
A 59-year-old Caucasian woman presented to our hospital
for biopsy of a rectal mass and diverting colostomy. Four
months earlier, she had developed rectal pain and
bleeding. Colonoscopy had revealed a large rectal mass;
pathology was consistent with a neuroendocrine
carcinoma. A labeled octreotide scan was positive in
the area of the tumor and the para-aortic lymph nodes,
but did not show hepatic or bony involvement.
Laboratory values, obtained 3 days before surgery, are
shown (Table 1).
The patient had a history of mild asthma. She denied
any prior personal or family history of malignancy,
nephrolithiasis, parathyroid or other endocrine disease.
Her listed medications included sustained release
oxycodone 20 mg b.i.d., ibuprofen 400 mg t.i.d. p.r.n.,
montelukast 10 mg p.r.n., and zolpidem 10 mg p.r.n.
Exploration of the abdomen revealed a large mass and
enlarged lymph nodes along the iliac vessels. Diverting
sigmoid colostomy and repeat biopsy were performed
without complications. Pathology was consistent with a
large cell neuroendocrine carcinoma with ulceration and
focal infiltration.
The patient did well in the perioperative period,
requiring no blood products and remaining
hemodynamically stable on maintenance intravenous
(i.v.) fluids 0.45% saline at 100 ml/h. She tolerated
advancement of her diet within 24 h and required no
nasogastric suctioning. However, 2 days after her surgical
procedures, laboratory values were notable for a plasma
calcium of 12.5 mg/dl and an elevated venous CO2 of
31 meq/l consistent with a mild metabolic alkalosis. The
plasma phosphate was low. Over the next week, these
metabolic abnormalities became more exaggerated,
prompting the involvement of the renal consult service
(Table 2).
On specific questioning, the patient admitted to recent
and regular use of calcium carbonate antacids before her
hospitalization to treat symptoms of acid reflux. She had
self-administered 1500 mg calcium carbonate antacid on
the day of her surgery but denied ongoing intake since
that one dose. In addition to maintenance fluids, her only
medications were cefazolin 1 g i.v. every 8 h for three total
doses, metronidazole 500 mg i.v. every 8 h for three total
doses, i.v. morphine sulfate 2 mg every 4 h as needed, and
ondansetron 2 mg i.v. every 6 h as needed. Metoprolol per
OS 25 mg twice a day had been started on post-operative
day (POD) 3 for elevated blood pressure.
Examination revealed a thin, fatigued-appearing
Caucasian woman with a flat affect. Vital signs were
temperature 98.2 F, blood pressure 151/87 mm Hg, pulse
67 bpm, respiratory rate 18 bpm with room air oxygen
saturation of 98%. Mucous membranes were moist. Neck
exam revealed a normal-sized thyroid gland and no neck
masses. Jugular venous pressure was estimated at 6 cm
H2O. Lungs were clear to auscultation. Heart sounds were
regular with a II/VI systolic ejection murmur. The abdomen
was soft with active bowel sounds. The colostomy looked
healthy. There were no rashes, joint tenderness, or edema.
There were no focal neurological findings and the patient
was alert and oriented.
Initial differential diagnosis of the hypercalcemia and
metabolic alkalosis included milk–alkali syndrome from
ongoing (surreptitious) antacid ingestion, humoral
hypercalcemia of malignancy (HHM) due to parathyroid
hormone-related peptide (PTHrP), osteolytic
hypercalcemia due to unrecognized bone metastases or
primary hyperparathyroidism, either isolated or within the
syndrome of multiple endocrine neoplasia 1. She was felt
to have mild intravascular volume contraction in the
setting of hypercalcemia with exacerbation of her
alkalosis.
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She was advised against any further intake of antacids.
Intravenous fluids were changed on POD 8 to 0.9% normal
saline at 250 ml/hr. Her urine output increased to more
than 5 l/day. Despite this aggressive fluid resuscitation,
her plasma calcium and venous CO2 remained elevated.
On POD10, the rate of i.v. fluids was increased to 350 ml/h.
On POD11, she was noted to have developed worsening
hypertension and mild peripheral edema. Furosemide i.v.
10 mg boluses were added with mild improvement in her
metabolic profile (Table 3). Amlodipine per OS 5 mg twice
a day was added to treat the persistent systolic and
diastolic hypertension. On POD 13, additional test results
returned (Tables 4 and 5).
DIAGNOSIS
(1) Rectal large cell neuroendocrine carcinoma.
(2) HHM with metabolic alkalosis, induced by surgical
manipulation of the tumor.
CLINICAL FOLLOW-UP
The patient received treatment with one dose of pamidronate
60 mg i.v. and had her i.v. fluids slowly tapered as plasma
calcium improved. She was discharged on POD 15 with
plasma calcium 8.6 mg/dl and phosphate 1.4 mg/dl. Since
discharge, she has not returned to our hospital. No further
follow-up on her care is available.
DISCUSSION
Humoral hypercalcemia of malignancy
Hypercalcemia has been reported to occur in up to 20–30%
of patients with a malignancy at some time during the course
of their disease.1 A previous review of hypercalcemia
associated with malignancy found its detection to signify a
very poor prognosis, with approximately 50% of patients
dying within 30 days.2
HHM accounts for approximately 80% of the hypercalc-
emia cases caused by malignancy.3 The majority of the other
20% cases are owing to local osteolytic liberation of calcium
(e.g., in multiple myeloma) and, much more rarely, 1,25 OH
vitamin D production by lymphomas or ectopic PTH
secretion.4 HHM has been reported with a wide range of
tumor cell types, most often with squamous cell, breast, and
renal carcinomas.
Humoral hypercalcemia is a rare complication of tumors
of the gastrointestinal tract.5 Sakata’s6 recent report of a case
of HHM from a poorly differentiated colonic adenocarci-
noma noted 20 prior cases of HHM associated with colonic
Table 1 | Laboratory values 3 days before surgery
BWH unit SI unit Normal range SI normal range
Na 135 mmol/l 135 mmol/l 136–142 mmol/l 136–142 mmol/l
K 3.5 mmol/l 3.5 mmol/l 3.5–5.0 mmol/l 3.5–5.0 mmol/l
Cl 99 mmol/l 99 mmol/l 98–108 mmol/l 98–108 mmol/l
CO2 27 meq/l 27 mmol/l 23–32 mmol/l 23–32 mmol/l
BUN 9 mg/dl 3.2 mmol/l 9–25 mg/dl 3.2–8.9 mmol/l urea
Cr 0.5 mg/dl 44 mmol/l 0.7–1.3 mg/dl 50–110mmol/l
Glucose 87 mg/dl 4.8 mmol/l 54–118 mg/dl 3.0–6.6 mmol/l
Albumin 3.7 g/dl 37 g/l 3.7–5.4 g/dl 40–60 g/l
Calcium 10.3 mg/dl 2.57 mmol/l 8.8–10.5 mg/dl 2.20–2.58 mmol/l
Alkaline phosphatase 75 U/l 75 U/l 36–118 U/l 36–118 U/l
BUN, blood urea nitrogen.
Table 2 | Postoperative development of hypercalcemia and metabolic alkalosis
POD0 POD1 POD3 POD4 POD5 POD6 POD7
CO2 BWH (23–32 meq/l) SI (23–32 mmol/l) 30 31 31 32 30 32 33
Calcium BWH (8.8–10.5 mg/dl) SI (2.20–2.58 mmol/l) 11.4 10.8 12.5 12.3 13.5 14.9
Ionized calcium BWH/SI (1.13–1.32 mmol/l) 1.74 1.81 1.82
PO4 BWH (2.4–5.0 mg/dl) SI (0.77–1.61 mmol/l) 2.1
POD, post-operative day.
Table 3 | Laboratory values after initiation of high-rate saline intravenous fluids
POD8 POD9 POD10 POD11 POD12 POD13
CO2 BWH (23–32 meq/l) SI (23–32 mmol/l) 26 30 32 32 29 28
Creatinine BWH (0.7–1.3 mg/dl) SI (50–110mmol/l) 0.6 0.6 0.6 0.7 0.6 0.6
Calcium BWH (8.8–10.5 mg/dl) SI (2.20–2.58 mmol/l) 12.3 12.7 11.8 12.0 10.1 10.1
Ionized calcium BWH/SI (1.13–1.32 mmol/l) 1.71 1.53 1.49 1.38
PO4 BWH (2.4–5.0 mg/dl) SI (0.77–1.61 mmol/l) oassay 1.1 1.2 1.4
POD, post-operative day.
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malignancy. Fujita7 subsequently reported on a case of HHM
associated with an adenosquamous carcinoma of the sigmoid
colon, raising the number of previously reported cases in the
English literature to 22.
Gastrointestinal neuroendocrine tumors are relatively
uncommon tumors arising from the widely scattered
enterochromaffin cells. These tumors, along with similar
tumors originating from the lungs and thymus, have
traditionally been defined as ‘carcinoid tumors’. The majority
are slow-growing (well-differentiated neuroendocrine
tumors) and retain the ability to produce and secrete
biologically active amines. The tumors may present with
stereotypical clinical syndromes due to biological activity of
these amine products.8–10 Rarely, they may show aggressive
behavior and become highly malignant (poorly differentiated
neuroendocrine tumors or neuroendocrine carcinoma).
Hypercalcemia is a rare complication of these tumors. A
previous case report of hypercalcemia due to PTHrP
secretion by a hepatic carcinoid found only 10 other cases
of hypercalcemia associated with carcinoid tumors reported
between 1966 and 1994.11 Four additional cases of HHM due
to PTHrP secretion by a carcinoid tumor or neuroendocrine
carcinoma have been reported since this review, involving
tumors of the stomach, bronchus, thymus, and pancreas.12–15
In general, tumors that present with HHM are advanced and
apparent, although this may not be the case with neuroendo-
crine tumors.16
Parathyroid hormone related peptide
PTHrP was recognized in the late 1980s as the primary
mediator of HHM.17–19 The peptide has since been found to
have protean cellular expression, acting in a variety of
endocrine, paracrine, and autocrine systems both in embry-
ologic development and adult physiology (Table 6).20 PTHrP
is a 139–173 amino acid protein with N-terminal homology
to parathyroid hormone (PTH). Of the first 13 amino acids,
eight are identical to PTH. This homology is responsible for
the activation of a common G protein-coupled receptor, the
PTH/PTHrP or PTH1 receptor.21 Beyond this region, the
amino acid sequences of PTH and PTHrP have little in
common. Diagnosis of PTHrP-mediated hypercalcemia is
confirmed by assay measurement of the protein. The assay
used in the diagnosis of this case was an immunoradiometric
assay that identifies the first 86 amino acid sequence of
PTHrP. The assay does not crossreact with any fragments of
human PTH and has a detection threshold of 0.3 pmol/l22
(ARUP Laboratories, Salt Lake City, Utah)
PTHrP produces hypercalcemia through its combined
effects on bone and kidney. In bone (similar to PTH), the
peptide stimulates osteoblasts to increase their expression of
receptor activator of nuclear factor kappa B ligand, which,
through binding to receptor activator of nuclear factor kappa
receptors on osteoclasts, upregulates osteoclastogenesis and
osteoclast activity.23 PTHrP-induced bone resorption dra-
matically increases the pool of free calcium. Both PTHrP and
Table 4 | Endocrine test results
BWH unit SI unit BWH normal range SI normal range
PTH 5.0 pg/ml 0.55 pmol/l 10–65 pg/ml 1.1–7.2 pmol/l
25-Vitamin D 7 ng/ml 17 nmol/l 20–57 ng/ml 50–142 nmol/l
TSH 0.969 mIU/l 0.969 mIU/l 0.5–5.0 mIU/l 0.5–5.0 mIU/l
T4 9.9 mg/dl 127 nmol/l 5–11mg/dl 64–152 nmol/l
PTHrP 6.4 pmol/l 6.4 pmol/l 0.0–1.5 pmol/l 00–1.5 pmol/l
PTH, parathyroid hormone; PTHrP, parathyroid hormone-related peptide; TSH, thyroid-stimulating hormone.
Table 5 | Conversion of BWH to SI units
BWH normal range SI conversion SI normal range
Na 136–142 mmol/l 1.0 136–142 mmol/l
K 3.5–5.0 mmol/l 1.0 3.5–5.0 mmol/l
Cl 98–108 meq/l 1.0 98–108 mmol/l
CO2 23–32 mmol/l 1.0 23–32 mmol/l
BUN 9–25 mg/dl 0.357 3.2–8.9 mmol/l urea
Creatinine 0.7–1.3 mg/dl 88.4 50–110mmol/l
Glucose 54–118 mg/dl 0.05551 3.0–6.55 mmol/l
Albumin 3.7–5.4 g/dl 10 40–60 g/l
Calcium 8.8–10.5 mg/dl 0.2495 2.20–2.58 mmol/l
Ionized calcium 1.13–1.32 mmol/l 1.0 1.13–1.32 mmol/l
Phosphate 2.4–5.0 mg/dl 0.3229 0.77–1.6145 mmol/l
Alkaline phosphatase 36–118 U/l 1.0 36–118 U/l
25-Vitamin D 20–57 ng/ml 2.496 50–142 nmol/l
PTH 10–65 pg/ml 0.11 1.1–7.15 pmol/l
PTHrP (ARUP) 0.0–1.5 pmol/l 1.0 0.0–1.5 pmol/l
TSH 0.5–5.0 mIU/l 1.0 0.5–5.0 mIU/l
T4 5–11mg/dl 12.87 64–152 nmol/l
BUN, blood urea nitrogen; PTH, parathyroid hormone; PTHrP, parathyroid hormone-related peptide; TSH, thyroid-stimulating hormone.
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PTH act upon the kidney through their common PTH1
receptor, producing similar effects on calcium and phosphate
handling. The patient described here had hypercalcemia and
hypophosphatemia, as is commonly seen in primary
hyperparathyroidism. The peptides’ other actions, however,
are not identical. Experimental infusion with the homo-
logous N-terminal peptide fragments of PTHrP and PTH
produces similar increases in calcium reabsorption, cyclic
AMP excretion, and phosphaturia.24,25 However, infusion
with whole PTHrP leads to a drop in urinary bicarbonate
excretion rather than the increase in urinary bicarbonate
produced by PTH.26 This conservation of bicarbonate
may explain the metabolic alkalosis associated with
PTHrP-induced hypercalcemia. In contrast to this, primary
hyperparathyroidism is associated with a hyperchloremic
metabolic acidosis.
Management of humoral hypercalcemia of malignancy
Acute management of PTHrP-mediated hypercalcemia (as
with all types of hypercalcemia) includes aggressive volume
resuscitation followed by measures to increase calcium
excretion and decrease its further liberation from bone.4
Most patients with HHM are dehydrated and have a lowered
glomerular filtration rate due to a combination of poor PO
intake of fluids and renal water wasting (hypercalcemia
induces a reversible nephrogenic diabetes insipidus). Thus,
unless there is an obvious contraindication such as heart
failure or severe renal failure, high volumes of normal saline
should be prescribed, for example 200–500 ml/h. Volume
expansion increases glomerular filtration rate, leading to
more filtration of calcium. Furthermore, normal saline has a
calciuretic effect. The patient’s volume status and urine
output should be frequently assessed on such fluid therapy.
Only after the patient is well volume expanded, should loop
diuretics be prescribed. Loop diuretics further increase renal
calcium excretion but have the potential to exacerbate
volume depletion and cause electrolyte abnormalities such
as hypokalemia.
Bisphosphonates block osteoclast action on bone and are
the mainstay of treatment for hypercalcemia associated with
malignancy. Indications for bisphosphonate treatment in
HHM include symptomatic hypercalcemia and plasma
calcium 412 mg/dl (3 mmol/l).4 Pamidronate and zolendro-
nate are the most commonly used bisphosphonates in the
USA; additional agents such as clodronate are available
elsewhere. These drugs must be given i.v. but are generally
well tolerated. Importantly, the plasma calcium does not start
to fall until about 48 h after their administration. Hence,
therapy with bisphosphonates should be started early and
interim therapies such as aggressive resuscitation with
normal saline should be pursued. There are two difficulties
with the use of bisphosphonates in renal failure: firstly,
bisphosphonates are renally excreted, so lower dosing is
required; secondly, bisphosphonates can exacerbate renal
failure.27–29 Practical measures we use in our center include
dose adjustment as per the manufacturers’ guidelines,
administration at half the normal infusion rate and
concomitant administration of normal saline. In our
(unpublished) experience, exacerbation of renal failure is
rare. It is important to note that bisphosponates are the most
effective drugs at controlling hypercalcemia; therefore, they
will in many cases ultimately improve acute renal failure.
Calcitonin is still occasionally used in the initial treatment
of HHM (it works within hours) but its calcium-lowering
effects are limited. Octreotide has been used with variable
success in treating HHM associated with neuroendocrine
tumors.11,13 A monoclonal antibody to PTHrP has been
successful in treating hypercalcemia in HHM animal models,
but results in humans have not been published.30 Finally, the
occasional cancer patient with hypercalcemia may require
hemodialysis against a low calcium concentration dialysate.
Hemodialysis is reserved for patients who have severe
hypercalcemia and presumed irreversible renal failure (as
opposed to the mild–moderate prerenal failure described
above) and poor tolerance of i.v. normal saline.
Hypophosphatemia is commonly associated with HHM,
as described in our case. Causes include the phosphaturic
effect of PTHrP, poor food intake, and loop diuretics.
Intravenous phosphate should not be prescribed in this
setting because it can induce severe hypocalcemia, acute renal
failure, and seizures.31 Low dose per OS phosphate is
appropriate but the plasma calcium and the plasma calcium
 phosphate product should be closely monitored.
The ultimate therapy of HHM is that which specifically
treats the cancer. Gastrointestinal neuroendocrine carci-
nomas may be cured if surgical resection is possible. As
mentioned above, octreotide and octreotide analogs have
been used with some success in controlling the growth of
Table 6 | Normal PTHrP physiology
Tissue Expression Action
Cartilage Embryo Chondrocyte proliferation, endochondral bone formation
Mammary gland Embryo Development of epithelial rudiment and branching structure
Adult May regulate maternal calcium homeostasis
Tooth Embryo Osteoclast resorption of alveolar bone for tooth eruption
Skin Adult Basal keratinocyte proliferation, antagonist of differentiation and apoptosis
Hair Adult Antagonist of anagen phase of hair growth
Central nervous system Adult Protection of cerebellar granular cells against glutamate-triggered calcium neurotoxicity
Placenta Adult Regulation of placental–fetal calcium gradient
PTHrP, parathyroid hormone-related peptide.
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neuroendocrine carcinomas.11,13 Palliative radiation and che-
motherapy with cisplatin and etoposide may reduce symptoms
and prolong survival of patients with poorly differentiated
neuroendocrine malignancies such as our case.32–34
Finally, it should be noted that not all cases of
hypercalcemia in cancer patients will be associated with the
malignancy. Evaluation of hypercalcemia in these patients
should carefully consider not only HHM but also causes such
as previously undiagnosed primary hyperparathyroidism,
hyperthyroidism, or granulomatous disease, impaired calci-
uresis due to thiazide diuretics, and surreptitious intake of
calcium-containing antacids or vitamin D.4
SUMMARY
We report a case of hypercalcemia of malignancy due to
PTHrP that manifested after surgical manipulation of a rectal
neuroendocrine carcinoma. Clinical presentation was re-
markable for hypercalcemia and metabolic alkalosis, resistant
to aggressive volume resuscitation. Initial differential diag-
nosis included the milk–alkali syndrome and hyperparathy-
roidism, either primary or related to MEN1, with volume
contraction. These diagnoses were subsequently excluded and
the patient’s PTHrP level returned to more than four times
the upper range of normal values. Despite volume expansion
and measures to increase calciuresis, the hypercalcemia and
alkalosis in our case resolved only after i.v. bisphosphonate
treatment. Our case illustrates that hypercalcemia associated
with metabolic alkalosis is not always due to the milk–alkali
syndrome; HHM should also be considered in the differential
diagnosis, particularly in patients with known neoplasia.
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